European Medicines Agency executive director Thomas Lönngren talks to Maureen Kenny about transparency, funding headaches, why the pharmaceutical industry should be allowed to provide information about their drugs to patients, dealing with conflicts of interest among scientific experts and lots more besides...
Please login to read the full article.
